One caveat to our experimentation with these lines is a lack of isogenic iPSC controls which were not available for comparison, therefore we cannot exclude the possibility that those differences in amplitude of the immune response between healthy donors and ALS lines may mask any iMGL hyper-responsivity to NLRP3 and/or NLRC4 inflammasome activation. This evidence concerns the gene NLRC4 and amyotrophic lateral sclerosis.